Trials / Completed
CompletedNCT00493324
Study to Evaluate the Immune Response to Pneumococcal Vaccine in Alefacept-treated Adults With Chronic Plaque Psoriasis
An Open-Label Phase 4 Study in Adult Patients With Chronic Plaque Psoriasis to Evaluate the Immune Response to Pneumococcal Vaccine in Subjects Treated With Alefacept
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 43 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A vaccine causes the immune system to produce antibodies (immune response) to specific germs to protect the patient. This study evaluates the immune response to the pneumococcal vaccine in adults with Alefacept-treated chronic plaque psoriasis.
Detailed description
This is a 1 arm study designed to evaluate the immune response to pneumococcal vaccine in adults with Alefacept-treated chronic plaque psoriasis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | alefacept | Intramuscular |
| DRUG | polyvalent pneumococcal vaccine | Injection |
Timeline
- Start date
- 2007-07-01
- Primary completion
- 2008-07-01
- Completion
- 2008-07-01
- First posted
- 2007-06-28
- Last updated
- 2012-02-02
Locations
7 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00493324. Inclusion in this directory is not an endorsement.